| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23057 |
| Drug | Talquetamab |
| Brand | Talvey® |
| Indication | Talquetamab is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Assessment Process | |
| Rapid review commissioned | 20/09/2023 |
| Rapid review completed | 10/11/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talquetamab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/11/2023 |
| Pre-submission consultation with Applicant | 23/01/2024 |
| Full submission received from Applicant | 02/05/2024 |
| Preliminary review sent to Applicant | 12/12/2024 |
| NCPE assessment re-commenced | 05/02/2025 |
| Factual accuracy sent to Applicant | 10/04/2025 |
| NCPE assessment re-commenced | 18/04/2025 |
| NCPE assessment completed | 26/05/2025 |
| NCPE assessment outcome | The NCPE recommends that talquetamab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
